- Home
- ARQT vs CDTX Comparison
ARQT vs CDTX Comparison
Compare ARQT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- CDTX
- Stock Information
- Founded
- ARQT 2016
- CDTX 2012
- Country
- ARQT United States
- CDTX United States
- Employees
- ARQT N/A
- CDTX N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARQT Health Care
- CDTX Health Care
- Exchange
- ARQT Nasdaq
- CDTX Nasdaq
- Market Cap
- ARQT 2.1B
- CDTX 1.6B
- IPO Year
- ARQT 2020
- CDTX 2015
- Fundamental
- Price
- ARQT $16.93
- CDTX $66.91
- Analyst Decision
- ARQT Strong Buy
- CDTX Strong Buy
- Analyst Count
- ARQT 7
- CDTX 11
- Target Price
- ARQT $19.00
- CDTX $57.00
- AVG Volume (30 Days)
- ARQT 1.5M
- CDTX 448.8K
- Earning Date
- ARQT 11-05-2025
- CDTX 11-06-2025
- Dividend Yield
- ARQT N/A
- CDTX N/A
- EPS Growth
- ARQT N/A
- CDTX N/A
- EPS
- ARQT N/A
- CDTX N/A
- Revenue
- ARQT $263,464,999.00
- CDTX N/A
- Revenue This Year
- ARQT $72.46
- CDTX N/A
- Revenue Next Year
- ARQT $32.00
- CDTX N/A
- P/E Ratio
- ARQT N/A
- CDTX N/A
- Revenue Growth
- ARQT 99.50
- CDTX N/A
- 52 Week Low
- ARQT $8.03
- CDTX $10.14
- 52 Week High
- ARQT $18.15
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- ARQT 57.20
- CDTX 61.47
- Support Level
- ARQT $15.13
- CDTX $61.10
- Resistance Level
- ARQT $18.15
- CDTX $65.84
- Average True Range (ATR)
- ARQT 0.67
- CDTX 3.10
- MACD
- ARQT 0.08
- CDTX -0.23
- Stochastic Oscillator
- ARQT 60.00
- CDTX 86.27
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.